Narrative review: oral rapamycin's brain penetration beyond CSF evidence
This narrative review argues that undetectable rapamycin in cerebrospinal fluid does not mean the drug fails to enter brain tissue, citing human tissue and functional data plus mouse studies; direct measurement in intact human brain at therapeutic doses is still lacking. [1]
Automatic summary · not editorially reviewed
The key findings
The review challenges the belief that rapamycin cannot enter brain tissue because it is absent from cerebrospinal fluid. [1]
In humans, direct tissue sampling in glioblastoma detected rapamycin in brain at mTORC1-inhibitory concentrations. [1]
Direct measurement of the parent drug in intact human brain parenchyma at therapeutic doses is lacking. [1]
The source at a glance
- Study type / format
- Narrative review (abstract)
- Population / context
- Humans with glioblastoma, tuberous sclerosis complex, Alzheimer's disease or APOE4 status, plus mice, as described in the review
- Summary based on
- Study abstract
- Original publication
- October 9, 2026
Review question: does CSF absence mean no brain entry?
This narrative review examines a persistent belief among researchers: that rapamycin cannot penetrate brain tissue, based on its absence in cerebrospinal fluid (CSF). The authors synthesize clinical and preclinical evidence to challenge what they call the "CSF misconception." They describe four pharmacological factors that could explain why rapamycin is not reliably detected in CSF: high lipophilicity with sequestration in tissue, extreme binding to red cells and proteins, P-glycoprotein efflux at the blood-CSF barrier, and assay insensitivity. In their view, none of these supports the claim that rapamycin fails to enter brain tissue.
Supporting source [1]
Human tissue and functional signals reported in the review
In humans, the review reports that direct tissue sampling in glioblastoma detected rapamycin in brain at concentrations that inhibit mTORC1. It also lists functional measures described as showing activity in the brain: tumor regression and seizure control in tuberous sclerosis complex, preserved cerebral metabolism on PET in Alzheimer's disease, increased cerebral blood flow in APOE4 carriers, and prolonged antidepressant response. In mice, the review states that LC-MS/MS confirmed dose-dependent brain accumulation, and that rapamycin modulates mTORC1 signaling, autophagy, and synaptic, epigenetic and inflammatory pathways. These are findings reported by the review, not new experiments.
Supporting source [1]
Central gap: no direct human brain measurement at therapeutic doses
The review flags a central gap: direct measurement of the parent drug in intact human brain parenchyma at therapeutic doses is lacking. It concludes that CSF concentration is a flawed proxy for rapamycin's central nervous system penetration. For Alzheimer's disease and related dementias (ADRD) trials, it suggests tracking surrogate markers of mTORC1 inhibition, functional neuroimaging, clinical outcomes and ADRD fluid biomarkers. The authors call these pharmacodynamic measurements essential for rational design and interpretation of prevention trials for the aging brain.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a narrative review, not a new study. The human tissue data come from glioblastoma sampling, and the functional measures are described without full trial details. Direct measurement in intact human brain at therapeutic doses is reported as lacking.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Melin JM, Young NA, Camardo J. · europepmc.org · October 9, 2026